Auauniversity

AUA2024: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice CME Available: https://auau.auanet.org/node/40976 At the conclusion of this activity, participants will be able to: 1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing. 2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability. 3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer. 4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from:

AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/41097 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve TURBT skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc.

AUA2024: Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize Treatment CME Available: https://auau.auanet.org/node/41048 At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) 2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists. 3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents 5. Discuss potential future pharmacological pathways and therapies for OAB. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas

AUA2024: AUA Advanced Prostate Cancer Guidelines CME Available: https://auau.auanet.org/node/41027 At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing and genetic counseling. 2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations. 3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer. 4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines. 5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lant

Live from AUA2024: Highlights in Bladder Cancer CME Available: https://auau.auanet.org/node/41085 At the conclusion of this activity, participants will be able to: 1. Discuss the newly released amendment to the AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer. 2. Describe recent developments in the management of non-muscle invasive bladder cancer. 3. Review current management approaches for non-metastatic muscle-invasive bladder cancer. 4. Identify novel therapies and their mechanism of action in the management of advanced bladder cancer. ACKNOWLEDGEMENT This educational activity is supported by independent educational grant from: Merck & Co., Inc.

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management CME Available: https://auau.auanet.org/node/41040 At the conclusion of this activity, participants will be able to: 1. Identify clinically available data that can help assess risk of UTUC disease. 2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate. 3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy. 4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes. 5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy. ACKNOWLEDGEMENTS This educational activity is supported by independent educa

AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider CME Available: https://auau.auanet.org/node/41048 At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) 2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists. 3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents 5. Discuss potential future pharmacological pathways and therapies for OAB. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas

Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024) CME Available: https://auau.auanet.org/node/41056 At the conclusion of this activity, participants will be able to: 1. Discuss the third-line therapies available to treat OAB refractory to conservative techniques. 2. Effectively provide counseling regarding advanced treatment techniques with "friendly, nonthreatening" language that does not intimidate the patients. 3. Consider helpful techniques to optimize lead placement for sacral neuromodulation and be comfortable with troubleshooting the device. 4. Incorporate caveats that are important in the delivery of injections in the bladder for treatment of OAB. 5. Incorporate peripheral nerve stimulation options, including the traditional and newer techniques that will be discuss in detail, into their practice as they see fit. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas

AUA2024: 003IC Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice CME Available: https://auau.auanet.org/node/40976 At the conclusion of this activity, participants will be able to: 1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing. 2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability. 3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer. 4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants

Journal Club 101 Guest: Melissa Kaufman, MD, PHD, FACS Outline: Segment #1: History of peer review Segment #2: Models of peer review Segment #3: General review best practices Segment #4: General structure for manuscript review Segment #5: Granular aspects of manuscript review

BPH: Surgical Treatment Guest: Bilal Chughtai, MD Outline: Segment #1: Bladder Health Segment #2: Diagnostics Segment #3: Stents Segment #4: New MISTs

AUA2024: Surgical Laser Enucleation of the Prostate Guests: Amy Krambeck, MD and Mark Assmus, MD Outline: Segment #1: Why Enucleation Segment #2: What makes this course special? Segment #3: What is new this year compared to last year? Segment #4: What do you think makes this course unique? Segment #5: Who is the ideal participant?

AUA2024: A Specialized Masterclass for Single-port Robot-Assisted Surgery Guests: Simone Crivellaro, MD and Ahmed Ghazi MD, MHPE Outline: Segment #1 Topic: The need for ongoing surgical education given the rise in introduction of new technologies in urology. Segment #2 Topic: Current status of Hands-on skills courses in Urology Segment #3 Topic: History of hands on courses offered at AUA Segment #4 Topic: Educational approach for surgical training Segment #5 Topic: Single-port masterclass at AUA a step in a new direction

Update Series (2024) Lesson 1: A Case-Based Discussion of Priapism Guidelines Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

AUA2023 Take Home Messages Part 5 Take Home Messages: Take Home Messages: BPH/LUTS Speaker: Dr. Dean Elterman Take Home Messages: Imaging Speaker: Dr. Richard Matulewicz Take Home Messages: Robotic Surgery Speaker: Dr. Andrew Hung Take Home Messages: Surgical Education Speaker: Dr. Simone Thavaseelan

AUA2023 Take Home Messages Part 4 Take Home Messages: Increasing Representation in Urology Speaker: Dr Larissa Bresler Take Home Messages: Healthcare Disparities Speaker: Dr. Adam Murphy Take Home Messages: Transplantation Speaker: Dr. Jason Lee Take Home Messages: Female Urology/Incontinence Speaker: Dr. Yahir Santiago-Lastra

AUA2023 Take Home Messages Part 3 Take Home Messages: Infertility/Andrology Speaker: Dr. Joshua Halpern Take Home Messages: Sexual Dysfunction Speaker: Dr. Peter Tsambarlis Take Home Messages: Pediatrics Speaker: Dr. Kate Kraft Take Home Messages: Global Health/Humanitarian Speaker: Dr. Rajiv Singal

AUA2023 Take Home Messages Part 2 Take Home Messages: Basic Science (Benign) Speaker: Dr. Douglas Strand Take Home Messages: Reconstruction Speaker: Dr. Jessica DeLong Take Home Messages: Endourology/Stones Speaker: Dr. Noah Canvasser Take Home Messages: Infection/Inflammation Speaker: Dr. Chris Doiron

AUA2023 Take Home Messages Part 1 Take Home Messages: Basic Science (Malignant) Speaker: Dr. Douglas Scherr Take Home Messages: Kidney Cancer Speaker: Dr. Amy Luckenbaugh Take Home Messages: Bladder Cancer Speaker: Dr. Jennifer Taylor Take Home Messages: Prostate Cancer Speaker: Dr. Samuel Washington

PARPi: Management of Adverse Events (2024) CME Available: https://auau.auanet.org/node/39609 Release Date: January, 2024 Expiration Date: January, 2025 LEARNING OBJECTIVES: 1. Identify approved PARPi for prostate cancer and patients who may benefit from PARPi based therapy. 2. Evaluate available clinical safety and efficacy data for PARPi. 3. Describe indications and contraindications for PARPi in patients with advanced prostate cancer. 4. Identify how to manage adverse events that patients may experience while taking a PARPi. ACKNOWLEDGEMENTS: This educational activity is supported by an independent educational grant from: Pfizer, Inc.